2021
DOI: 10.21203/rs.3.rs-942036/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Determinants and Reasons for Switching Anti-Retroviral Regimen Among HIV-Infected Youth in a Large Township of South Africa (2002-2019)

Abstract: Background: There are limited data exploring antiretroviral therapy(ART) changes and time to change among South Africa young people living with HIV/AIDS. Objective: We describe the time to first drug switch, which includes ART regimen change (three drug switch) and substitutions (single drug switch). We describe common reasons for ART switch among young people aged 10 to 24 years in South Africa.Methods: We conducted a retrospective cohort study at a primary health care clinic in Cape Town, South Africa, provi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…This data is consistent with reports from South Africa, Latin America, the UK, and India, where switches due to drug intolerance range from 23.3% to 64%. 24,25,26 The second most frequent cause of switch was virologic failure ( n = 137; 17.2%). The risk of pretreatment HIV drug resistance could be higher in low and middle-income countries, however in Colombia in 2017, it was 6.3% for non-nucleoside reverse transcriptase inhibitors (NNRTI), 27 which is moderate and could be underestimated considering that genotypification is not routinely performed before ART initiation.…”
Section: Discussionmentioning
confidence: 99%
“…This data is consistent with reports from South Africa, Latin America, the UK, and India, where switches due to drug intolerance range from 23.3% to 64%. 24,25,26 The second most frequent cause of switch was virologic failure ( n = 137; 17.2%). The risk of pretreatment HIV drug resistance could be higher in low and middle-income countries, however in Colombia in 2017, it was 6.3% for non-nucleoside reverse transcriptase inhibitors (NNRTI), 27 which is moderate and could be underestimated considering that genotypification is not routinely performed before ART initiation.…”
Section: Discussionmentioning
confidence: 99%